Total Payments
$7,744
2024 Payments
$817.27
Companies
33
Transactions
250
Medicare Patients
9,050
Medicare Billing
$946,284
Payment Breakdown by Category
Food & Beverage$6,020 (77.7%)
Travel$1,517 (19.6%)
Education$189.98 (2.5%)
Other$18.16 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,020 | 242 | 77.7% |
| Travel and Lodging | $1,517 | 5 | 19.6% |
| Education | $189.98 | 2 | 2.5% |
| Entertainment | $18.16 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Medtronic Vascular, Inc. | $2,770 | 32 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $990.64 | 30 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $536.71 | 29 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $486.09 | 24 | $0 (2024) |
| Amgen Inc. | $428.90 | 26 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $365.14 | 18 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $335.42 | 19 | $0 (2024) |
| Abbott Laboratories | $261.13 | 3 | $0 (2019) |
| PFIZER INC. | $233.39 | 15 | $0 (2024) |
| Astellas Pharma US Inc | $189.98 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $817.27 | 40 | Janssen Pharmaceuticals, Inc ($177.25) |
| 2023 | $737.27 | 35 | Janssen Pharmaceuticals, Inc ($141.59) |
| 2022 | $25.63 | 1 | Medtronic, Inc. ($25.63) |
| 2021 | $11.24 | 1 | Medtronic, Inc. ($11.24) |
| 2020 | $1,222 | 28 | Medtronic Vascular, Inc. ($959.86) |
| 2019 | $2,358 | 41 | Medtronic Vascular, Inc. ($1,362) |
| 2018 | $1,075 | 42 | Boehringer Ingelheim Pharmaceuticals, Inc. ($179.62) |
| 2017 | $1,498 | 62 | Medtronic Vascular, Inc. ($341.68) |
All Payment Transactions
250 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $26.23 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.80 | General |
| Category: DIABETES | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $26.82 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: DIABETES | ||||||
| 10/23/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $28.66 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/26/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $29.47 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 09/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: DIABETES | ||||||
| 09/04/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $31.35 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/28/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/21/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $21.57 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/14/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: Cardiology | ||||||
| 08/07/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.92 | General |
| Category: DIABETES | ||||||
| 07/31/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $31.34 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 07/24/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/17/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $23.59 | General |
| Category: Genetic Disease | ||||||
| 07/12/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $6.56 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 07/10/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $20.46 | General |
| Category: Cardiology | ||||||
| 06/25/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $25.04 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 06/05/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $18.57 | General |
| Category: Cardiovascular | ||||||
| 05/29/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $22.30 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/23/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $30.61 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.62 | General |
| Category: DIABETES | ||||||
| 05/08/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/08/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $2.24 | General |
| Category: CARDIOVASCULAR | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 3,173 | 3,472 | $1.3M | $310,595 |
| 2022 | 24 | 2,212 | 3,885 | $1.3M | $258,910 |
| 2021 | 21 | 1,499 | 3,937 | $833,690 | $200,526 |
| 2020 | 27 | 2,166 | 2,913 | $509,113 | $176,253 |
Total Patients
9,050
Total Services
14,207
Medicare Billing
$946,284
Procedure Codes
99
All Medicare Procedures & Services
99 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 640 | 653 | $578,892 | $115,524 | 20.0% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 52 | 53 | $95,400 | $42,584 | 44.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 166 | 166 | $85,018 | $23,260 | 27.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 219 | 255 | $103,336 | $20,559 | 19.9% |
| 93356 | Heart muscle strain imaging | Office | 2023 | 562 | 573 | $77,355 | $19,618 | 25.4% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 91 | 91 | $82,157 | $19,246 | 23.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 90 | 90 | $57,150 | $17,112 | 29.9% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 592 | 650 | $44,200 | $13,682 | 31.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 59 | 91 | $43,701 | $12,928 | 29.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 37 | 92 | $29,602 | $9,383 | 31.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 27 | 28 | $17,271 | $4,160 | 24.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 300 | 333 | $24,294 | $4,025 | 16.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 31 | 31 | $26,513 | $1,818 | 6.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 34 | 35 | $12,128 | $1,243 | 10.2% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 52 | 53 | $4,558 | $1,136 | 24.9% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 124 | 143 | $4,290 | $995.28 | 23.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 18 | 18 | $2,430 | $835.65 | 34.4% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 16 | 16 | $5,568 | $820.56 | 14.7% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Office | 2023 | 13 | 13 | $3,185 | $610.48 | 19.2% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 23 | 60 | $2,400 | $608.40 | 25.4% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Office | 2023 | 13 | 13 | $1,976 | $289.77 | 14.7% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 14 | 15 | $600.00 | $157.05 | 26.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 466 | 471 | $447,471 | $75,538 | 16.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 446 | 729 | $356,574 | $74,963 | 21.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 22 | 1,320 | $67,320 | $22,338 | 33.2% |
About Dr. Armin Barekatain, MD
Dr. Armin Barekatain, MD is a Cardiovascular Disease healthcare provider based in Laguna Hills, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2012. The National Provider Identifier (NPI) number assigned to this provider is 1982950572.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Armin Barekatain, MD has received a total of $7,744 in payments from pharmaceutical and medical device companies, with $817.27 received in 2024. These payments were reported across 250 transactions from 33 companies. The most common payment nature is "Food and Beverage" ($6,020).
As a Medicare-enrolled provider, Barekatain has provided services to 9,050 Medicare beneficiaries, totaling 14,207 services with total Medicare billing of $946,284. Data is available for 4 years (2020–2023), covering 99 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Laguna Hills, CA
- Active Since 08/01/2012
- Last Updated 10/03/2023
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1982950572
Products in Payments
- CoreValve Evolut (Device) $1,303
- Azure (Device) $937.39
- PRADAXA (Drug) $819.27
- XARELTO (Drug) $486.09
- ENTRESTO (Drug) $381.09
- LifeVest (Device) $365.14
- ELIQUIS (Drug) $250.67
- Corlanor (Drug) $245.55
- JARDIANCE (Drug) $171.37
- FARXIGA (Drug) $168.73
- Repatha (Biological) $167.02
- Reveal LINQ (Device) $161.27
- LEQVIO (Drug) $155.62
- PRALUENT ALIROCUMAB INJECTION (Biological) $149.22
- BRILINTA (Drug) $144.39
- Resolute (Device) $142.07
- Confirm Rx (Device) $124.36
- HeartMate 3 Left Ventricular Dev (Device) $117.76
- EKOSONIC (Device) $112.48
- Claria MRI (Device) $112.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Laguna Hills
Dr. Roxana Ghashghaei, M.d, M.D
Cardiovascular Disease — Payments: $319,402
Cardiovascular Disease $319,402
Sasan Ghaffari, Md, MD
Cardiovascular Disease — Payments: $45,587
Cardiovascular Disease $45,587
Dr. Michael Gault, M.d, M.D
Cardiovascular Disease — Payments: $39,247
Cardiovascular Disease $39,247
Dr. Jeffrey Feiner, M.d, M.D
Cardiovascular Disease — Payments: $30,343
Cardiovascular Disease $30,343
Paul Drury, M.d, M.D
Cardiovascular Disease — Payments: $28,532
Cardiovascular Disease $28,532
Dr. Daniel Lamont, M.d, M.D
Cardiovascular Disease — Payments: $26,724
Cardiovascular Disease $26,724